Tag Archives: Cdiffense Phase III clinical program

Sanofi vaccines division Sanofi Pasteur initiated Cdiffense Phase III Study of investigational vaccine for prevention of primary symptomatic Clostridium difficile infection (CDI)

Posted on 6, August 2013 by EuropaWire PR Editors

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program … Read the full press release →

Posted in Business, France, Healthcare, Pharma & Biotech, Science

Tagged Alain Bernal, C. diff, Cdiffense, Cdiffense Phase III clinical program, Cdiffense trial, Clostridium difficile infection, intestinal disease, Investigational Clostridium Difficile Vaccine, John Shiver PhD, life-threatening infections, Sanofi, Sanofi Pasteur, Sanofi vaccines division, Susan Watkins, symptomatic Clostridium difficile infection (CDI)